Ascendis Pharma A/S’s (ASND) “Overweight” Rating Reiterated at Cantor Fitzgerald

Posted by Brenda Bartman on Sep 28th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $300.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 31.67% from the company’s previous close.

Several other brokerages have also commented on ASND. Stifel Nicolaus cut their price target on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Bank of America cut their price target on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Wedbush restated an “outperform” rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. Finally, Raymond James Financial lowered Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price target on the stock. in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $310.75.

Check Out Our Latest Report on Ascendis Pharma A/S

Ascendis Pharma A/S Trading Up 1.0%

Ascendis Pharma A/S stock traded up $2.25 during trading hours on Friday, hitting $227.85. The company had a trading volume of 98,940 shares, compared to its average volume of 694,669. The firm has a market cap of $14.21 billion, a P/E ratio of 17.68 and a beta of 0.35. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. Ascendis Pharma A/S has a 1 year low of $186.05 and a 1 year high of $282.15. The company has a 50-day moving average price of $251.52 and a two-hundred day moving average price of $242.29.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). The company had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post 3.69 earnings per share for the current year.

Insider Activity

In related news, Director Jean-Jacques Bienaimé bought 2,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were bought at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the purchase, the director directly owned 2,900 shares of the company’s stock, valued at approximately $714,357. This trade represents a 222.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Caitong International Asset Management Co. Ltd acquired a new stake in Ascendis Pharma A/S in the fourth quarter worth about $42,000. EverSource Wealth Advisors LLC boosted its holdings in Ascendis Pharma A/S by 34.0% in the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 69 shares in the last quarter. Allworth Financial LP boosted its holdings in Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 122 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Ascendis Pharma A/S by 94.9% in the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 148 shares in the last quarter. Finally, IFP Advisors Inc boosted its holdings in Ascendis Pharma A/S by 3,491.7% in the second quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 419 shares in the last quarter.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.